Do you want to read an article? Please log in or register.
Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors
Am J Gastroenterol.
Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Vande Casteele N, Boland BS, Prokop L, Murad MH, DʼHaens G, Feagan BG, Sandborn WJ, Jairath V, Singh S
doi: 10.14309/ajg.0000000000000596.
Inflammatory Bowel Disease
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX® for active, mild-to-moderate ulcerative colitis
United European Gastroenterol J.
Danese S, Hart A, Dignass A, Fiorino G, Louis E, Bonovas S, D'Haens G, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L
doi: 10.1177/2050640619864848.
Inflammatory Bowel Disease
JAK inhibitors safety in ulcerative colitis: practical implications
J Crohns Colitis.
Agrawal M, Kim ES, Colombel JF
doi: 10.1093/ecco-jcc/jjaa017.
Inflammatory Bowel Disease
Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy
J Crohns Colitis.
Panés J, Lindsay JO, Teich N, Lindgren S, Colombel JF, Cornillie F, Flynn HA, Huyck S, Stryszak P, Yao R, Philip G, Reinisch W
doi: 10.1093/ecco-jcc/jjz048.
Inflammatory Bowel Disease
Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis
Inflamm Bowel Dis.
Adedokun OJ, Gunn GR 3rd, Leu JH, Gargano C, Xu Z, Sandborn WJ, Rutgeerts P5, Shankar G
doi: 10.1093/ibd/izz003.
Inflammatory Bowel Disease
A Phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis
Gastroenterology.
Henn MR, O'Brien EJ, Diao L, Feagan BG, Sandborn WJ, Huttenhower C, Wortman JR, McGovern BH, Wang-Weigand S, Lichter DI, Chafee M, Ford CB, Bernardo P, Zhao P, Simmons S, Tomlinson A, Cook D, Pomerantz R, Misra BK, Auninš JG, Trucksis M
doi: 10.1053/j.gastro.2020.07.048.
Inflammatory Bowel Disease
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study
United European Gastroenterol J
Pugliese D, Privitera G, Rogai F, Variola A, Viola A, Laterza L, Privitera AC, Allocca M, Bossa F, Cappello M, Daperno M, Lorenzon G, Mazzuoli S, Principi M, Sablich R, Moser L, Ferronato A, Traini S, Tapete G, Bodini G, Girolamo MD, Grossi L, Mocci G, Ricci C, Saibeni S, Festa S, Spagnuolo R, Cortelezzi CC, Mocciaro F, Rizzello F, Armuzzi A, on behalf on the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
doi: 10.1177/2050640620974308
Inflammatory Bowel Disease
Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses
United European Gastroenterol J.
Pantavou K, Yiallourou AI, Piovani D, Evripidou D, Danese S, Peyrin-Biroulet L, Bonovas S, Nikolopoulos GK
doi: 10.1177/2050640619883566.
RECOMMENDED
Inflammatory Bowel Disease
First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Clin Gastroenterol Hepatol.
Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ
doi: 10.1016/j.cgh.2020.01.008.